News Articles

Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022 OSAKA, Japan -Thursday 12 May 2022  

- Strong Performance Against FY2021 Management Guidance with Underlying Revenue Growth of +7.4% (Reported Revenue Growth +11.6%) and Strength Across Key Business Areas - Highest Total Number of Approvals for Takeda in a Fiscal Year Across Japan (4 NMEs), China (3 NMEs), the U.S. (2 NMEs),...

Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories -Friday 29 April 2022  

- Groundbreaking “Make to Order” Process for Stem Cell Therapy Wins Supply Chain Category − Vaccine Facility in Singen, Germany, Wins Pharma 4.0 Category for Applying Digital Technologies in Production Process − Recognition Illustrates Takeda’s Patient-Centricity Throughout its...

Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in... -Friday 22 April 2022  

Data Include Exploratory Analysis Showing LIVTENCITY Treated Patients With Post-Transplant Cytomegalovirus (CMV) Infections/Disease Had Reductions in Hospitalizations (34.8%; p=0.021) and Length of Hospital Stay (53.8%; p=0.029) Compared to Those Treated With Conventional Antiviral...

Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan -Tuesday 19 April 2022  

 − Nuvaxovid Intramuscular Injection, containing Matrix-MTM adjuvant, is the first recombinant protein-based COVID-19 vaccine approved for use in Japan − Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical...

Takeda Announces Completion of Acquisition of Own Shares -Wednesday 13 April 2022  

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today provided an update on the status and announced the completion of the acquisition of its own shares, which has been carried out pursuant to the provision of its Articles of Incorporation in...

Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12... -Tuesday 12 April 2022  

SHP643-301 is A Multicenter, Open-Label Phase 3 Study to Evaluate Safety, PK, Pharmacodynamics, And Clinical Activity/Outcomes of TAKHZYRO for Prevention Against Acute Attacks of HAE in Pediatric Patients 2 To

Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners -Wednesday 6 April 2022  

− Award Celebrates Outstanding Research With a Focus in 2022 on Gastroenterology − Winners’ Discoveries Reveal the Power of the Gut Microbiome − Recipients Receive Unrestricted $200,000 USD Award (BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) and the New York Academy of...

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting -Friday 1 April 2022  

(BUSINESS WIRE) -- Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors will propose two new candidates for independent external directors at the 146th Ordinary Meeting of Shareholders on June 29, 2022. The new candidates, Kimberly A. Reed and John Maraganore, who – if...

Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary... -Tuesday 29 March 2022  

− TAKHZYRO Approved for Adult and Pediatric Patients 12 Years of Age and Older1 − Approval Based on Results of Global Phase 3 HELP Study™, Phase 3 HELP OLE and a Phase 3 Study in Japanese Patients Evaluating the Efficacy and Safety of TAKHZYRO1 − In a Japan-Specific Phase 3...

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary... -Monday 28 February 2022  

− Interim Real-World Data from Phase 4 EMPOWER Study Show Attack Rate Reduction and Improvement in Treatment Satisfaction and Other Patient-Reported Outcome Scores1 − Interim Patient-Reported Outcomes Showed a Reduction of Monthly Attack Rates in New Users and Showed Sustained...

Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study... -Friday 18 February 2022  

- Data on Patients with Complex Crohn’s Perianal Fistulas Were Presented at the European Crohn’s and Colitis Organisation (ECCO) 2022 Congress1 - INSPIRE is the First Observational, Multicenter, Post-Approval, Open-Enrollment Study Designed to Evaluate the Real-World Effectiveness and...

Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum -Monday 7 February 2022  

(BUSINESS WIRE) -- Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topline growth of its 14 global brands. Based on the strong third-quarter results and business momentum, the...

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare... -Tuesday 11 January 2022  

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030. Presenting at the...

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies... -Tuesday 11 January 2022  

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1...

Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721 -Wednesday 22 December 2021  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for TAK-721 (budesonide oral...

Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of... -Wednesday 8 December 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present a total of 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021 in Atlanta, Georgia....

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in... -Wednesday 8 December 2021  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R)...

Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People... -Wednesday 24 November 2021

- In the Phase 3 SOLSTICE study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R) CMV infection/disease achieved confirmed CMV DNA level < LLOQ at Week 8 with LIVTENCITY (56%; n=131/235), compared to those treated with conventional antiviral...

Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange... -Tuesday 2 November 2021

Takeda applied for selection to the "Prime Market" of the TSE Corporate Governance Report based on the revised Corporate Governance Code also filed with TSE Published updated corporate governance related documents to help enhance transparency of its corporate...

Takeda Announces Acquisition of Own Shares -Saturday 30 October 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph...